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Editorial Comment
Spasticity After Stroke: What’s the Catch?
Motor deficits are the most common impairment acutely after
stroke and persist in nearly half of all patients.1,2 Although
much focus is on hemiparesis in this setting, injury to the
motor system does not produce a homogenous clinical syn-
drome. Instead, weakness may be accompanied by other
negative findings such as slowness and fatigue and by
positive findings such as synkinesia and spasticity.
Spasticity is a state of increased tone with exaggerated
reflexes resulting from upper motor neuron injury. It is a
condition of many contrasts. Reduced activity in one area, the
descending motor tracts, results in increased activity in another
area, the skeletal muscles. Spasticity is common across neuro-
logical conditions, yet accurate measurement is difficult. It is
associated with weakness, yet its maintenance is critical to
function in some patients. Importantly, spasticity remains a key
dividing point among major schools of physiotherapy, with
some aiming to inhibit3 and others aiming to encourage4 spas-
ticity and its accompanying motor abnormalities. The medical
system expends substantial resources to reduce spasticity with
methods that include botulinum toxin injection, intrathecal
medication, oral pharmacological agents, and physical/occupa-
tional therapy. Yet, limited information is available on its
prevalence and significance after stroke. Indeed, in a recent
review, Barnes5 noted the limited availability of quality data on
the prevalence of spasticity after stroke.
Some of those data are now available. Sommerfeld et al6 studied
consecutive patients with a first stroke over a 10-month period.
Among 95 patients assessed a mean of 5 days after stroke, 21% had
spasticity and 81% had hemiparesis. Three months later, 19% were
spastic and 67% were hemiparetic. Of note, only 28% of the
hemiparetic patients had spasticity. A weakness of the study is that
the authors provided limited detail as to precisely which muscles
were affected by spasticity. Values for spasticity prevalence in this
study are not likely an underestimation, because any measurable
increase in tone was considered to constitute spasticity. Study results
suggest that although spasticity is associated with greater deficits
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and disability, it is present in a minority of stroke patients and in a
minority of hemiparetic stroke patients.
The indications for reducing spasticity after stroke remain a topic
of ongoing investigation. A compelling argument can be made for
treating spasticity after stroke in certain specific instances, eg, when
the goal is to prevent an incipient contracture or to reduce a regional
pain syndrome such as that associated with a hemiplegic shoul-
der.7–9 However, improvement in overall coordinated movement or
in disability after stroke as a general response to reduction of
spasticity remains to be firmly established.10 Indeed, treatments
targeting spasticity have often had difficulty demonstrating func-
tional benefit.11 Dobkin8 recently noted in this context, “With the
exception of lessening painful or disruptive spasms and dystonic
postures, drugs in general do not decrease impairments or lessen
disabilities.”
A range of additional studies is needed to refine guidelines
for treating spasticity after stroke. As with so many aspects of
stroke, response to spasticity-related therapy may be maxi-
mum in a subset of patients or may be realized in performance
of a subset of motor tasks.12 The effects of such therapy may
be best measured not by general neurological outcome scales
but rather by the use of end points most relevant to effects of
spasticity.13 Newer instrumentation-based methods might
also improve measurement of spasticity.14,15 Clinical trials
may further clarify the utility of specific approaches to reduce
spasticity. The study by Sommerfeld et al,6 by providing
quality data on the prevalence and functional significance of
spasticity after stroke, is an important step.
Steven C. Cramer, MD, Guest Editor
University of California, Irvine
Department of Neurology
Irvine, California
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